|
Aug 5
|
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series
|
|
Jul 30
|
Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Jul 25
|
One Enanta Pharmaceuticals Insider Raised Their Stake In The Previous Year
|
|
Jul 15
|
Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series
|
|
Jun 11
|
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
|
|
May 27
|
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
|
|
May 22
|
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
|
|
May 15
|
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
|
|
May 15
|
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
|
|
May 12
|
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
|
|
May 12
|
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot
|
|
May 12
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
|
|
Apr 8
|
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
|
|
Mar 12
|
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
|
|
Feb 15
|
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns
|
|
Feb 15
|
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock
|
|
Feb 14
|
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
|
|
Feb 10
|
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
|
|
Feb 10
|
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot
|
|
Feb 10
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
|